Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Roivant Sciences Ltd
(NQ:
ROIV
)
11.92
+0.01 (+0.08%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roivant Sciences Ltd
< Previous
1
2
3
4
5
6
7
8
Next >
These 2 Growth Stocks Might Be Incredibly Undervalued Right Now
April 20, 2023
These two biopharma stocks could be poised for a major growth spurt.
Via
The Motley Fool
EXCLUSIVE: Joe Biden Tops 2024 Election Betting Odds, How Negative Headlines And Indictment Move Trump Ahead Of DeSantis
April 17, 2023
While the 2024 U.S. presidential election may seem a long way off, polls to see who is favored by voters and betting odds for the next White House occupant have ramped up.
Via
Benzinga
These 3 Nasdaq Stocks Are on Fire Today: Here's Why
April 17, 2023
A high-dollar buyout is lighting a fire underneath these three Nasdaq stocks today.
Via
The Motley Fool
Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom
April 17, 2023
Merck is branching into immune-mediated diseases with this takeover.
Via
Investor's Business Daily
Prometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market Session
April 17, 2023
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 70.1% to $193.93...
Via
Benzinga
Analyst Expectations for Roivant Sciences's Future
March 16, 2023
Via
Benzinga
Roivant Sciences Highlights Topline Data From Atopic Dermatitis Drug In Patients As Young As 2 Years
March 15, 2023
Via
Benzinga
Expert Ratings for Roivant Sciences
February 13, 2023
Via
Benzinga
Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory
April 04, 2023
From
Lokavant
Via
Business Wire
Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research
April 04, 2023
From
Lokavant
Via
Business Wire
Roivant Sciences's Earnings Outlook
February 10, 2023
Via
Benzinga
Where Roivant Sciences Stands With Analysts
January 19, 2023
Via
Benzinga
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
March 29, 2023
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine.
Via
InvestorPlace
Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
March 28, 2023
From
Covant Therapeutics
Via
GlobeNewswire
Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 21, 2023
Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share.
Via
Benzinga
Why Shares of Roivant Sciences Were Down Tuesday
March 21, 2023
After a run-up last week prompted by positive clinical trial results, the stock has given back its recent gains.
Via
The Motley Fool
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
March 15, 2023
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.
Via
InvestorPlace
Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
March 15, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis
March 14, 2023
From
Roivant Sciences
Via
GlobeNewswire
Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs
March 14, 2023
PVTX-321 and PVTX-405 Achieve Development Candidate Nomination
From
Roivant Sciences
Via
GlobeNewswire
Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement
March 07, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Sciences Announces Change to its Board of Directors
February 21, 2023
From
Roivant Sciences
Via
GlobeNewswire
Immunovant Could Potentially Be An M&A Target, Writes Analyst
February 15, 2023
Via
Benzinga
Mixed Signals On Valentine's Day: How Stocks Are Reacting To January Inflation Data
February 14, 2023
Inflation cooled slightly in January, but saw increases in some areas due to the impact of surging food, energy and shelter prices on consumers, the U.S Labor Department said Tuesday.
Via
Benzinga
Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update
February 13, 2023
From
Roivant Sciences
Via
GlobeNewswire
Earnings Scheduled For February 13, 2023
February 13, 2023
Companies Reporting Before The Bell • EuroDry (NASDAQ:EDRY) is expected to report quarterly earnings at $2.68 per share on revenue of $21.20 million.
Via
Benzinga
Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares
February 02, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Sciences Announces Proposed Public Offering of Common Shares
February 01, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023
January 30, 2023
From
Roivant Sciences
Via
GlobeNewswire
Roivant Touts Encouraging Early Data From Ulcerative Colitis Candidate
January 04, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.